Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer (CA9CRM)

This study has been terminated.
(Difficult for recruiting)
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT00942058
First received: June 17, 2009
Last updated: January 28, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2013
  Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)